We serve Chemical Name:1-methoxy-4-phenylpyridin-1-ium,tetrafluoroborate CAS:63123-42-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-methoxy-4-phenylpyridin-1-ium,tetrafluoroborate
CAS.NO:63123-42-2
Synonyms:EINECS 263-884-9;1-Methoxy-4-phenylpyridinium tetrafluoroborate;MFCD00274306;1-methoxy-4-phenylpyridin-1-ium tetrafluoroborate
Molecular Formula:C12H12BF4NO
Molecular Weight:273.03400
HS Code:
Physical and Chemical Properties:
Melting point:90-95ºC(lit.)
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:13.11000
Exact Mass:273.09500
LogP:2.99950
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 263-884-9 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-methoxy-4-phenylpyridin-1-ium tetrafluoroborate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Methoxy-4-phenylpyridinium tetrafluoroborate Use and application,EINECS 263-884-9 technical grade,usp/ep/jp grade.
Related News: Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit Oxo(2,2,2-trifluoroethoxy)acetic acid manufacturers One of the main benefits of biocatalysis is that it increases conversion efficiency for significantly higher yields with fewer by-products, equating to faster and more cost-effective production. (2,4,6-Trimethoxyphenyl)methanol suppliers TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, Methyl (5Z)-5-octenoate vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit Oxo(2,2,2-trifluoroethoxy)acetic acid manufacturers One of the main benefits of biocatalysis is that it increases conversion efficiency for significantly higher yields with fewer by-products, equating to faster and more cost-effective production. (2,4,6-Trimethoxyphenyl)methanol suppliers TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, Methyl (5Z)-5-octenoate vendor & factory.
